This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imro, M. A. Articles by Protti, M. P. Search for Related Content PubMed PubMed Citation Articles by Imro, M. A. Articles by Protti, M. P.

Major Histocompatibility Complex Class I Restricted Cytotoxic T Cells Specific for Natural Melanoma Peptides Recognize Unidentified Shared Melanoma Antigen(s)¹

Laboratory of Tumor Immunology [M. A. I., S. M., G. C., M. B., C. R., M. P. P.], Gene Therapy Program [V. R., C. T.], Universita Vita-Salute [C. R.], and Cancer Immunotherapy and Gene Therapy Program [M. A. I., S. M., V. R., G. C., M. B., C. R., C. T., M. P. P.], Scientific Institute H. San Raffaele, 20132 Milan, Italy

CTLs were generated in vitro from two healthy donors and one melanoma patient by stimulation of CD8⁺ T cells with autologous dendritic cells pulsed with natural melanoma peptides (NMPs), obtained by acid treatment of HLA-matched melanoma cells. CTLs showed MHC class I-restricted melanoma-specific cytolytic activity. Importantly, CTLs from the patient, induced with NMPs obtained from an allogeneic HLA-A-matched melanoma, killed the autologous tumor. COS-7 cells cotransfected with the cDNA of 13 melanoma antigens and the HLA-A1-restricting allele did not induce cytokines release from NMP-specific CTLs, suggesting that they recognize unidentified shared melanoma antigens and that they may be valuable for identification of new tumor antigens. These results strongly support the use of autologous and/or allogeneic NMP-pulsed dendritic cells as cancer vaccines in patients whose neoplasms do not express or have lost expression of known tumor antigens.

This article has been cited by other articles:

				E. Tassi, V. Facchinetti, S. Seresini, A. Borri, G. Dell'Antonio, C. Garavaglia, G. Casorati, and M. P. Protti Peptidome from Renal Cell Carcinoma Contains Antigens Recognized by CD4+ T Cells and Shared among Tumors of Different Histology. Clin. Cancer Res., August 15, 2006; 12(16): 4949 - 4957. [Abstract] [Full Text] [PDF]

				M. Crosti, R. Longhi, G. Consogno, G. Melloni, P. Zannini, and M. P. Protti Identification of Novel Subdominant Epitopes on the Carcinoembryonic Antigen Recognized by CD4+ T Cells of Lung Cancer Patients. J. Immunol., April 15, 2006; 176(8): 5093 - 5099. [Abstract] [Full Text] [PDF]

				G. Campi, M. Crosti, G. Consogno, V. Facchinetti, B. M. Conti-Fine, R. Longhi, G. Casorati, P. Dellabona, and M. P. Protti CD4+ T Cells from Healthy Subjects and Colon Cancer Patients Recognize a Carcinoembryonic Antigen-specific Immunodominant Epitope Cancer Res., December 1, 2003; 63(23): 8481 - 8486. [Abstract] [Full Text] [PDF]

				V. Russo, S. Tanzarella, P. Dalerba, D. Rigatti, P. Rovere, A. Villa, C. Bordignon, and C. Traversari Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response PNAS, February 29, 2000; 97(5): 2185 - 2190. [Abstract] [Full Text] [PDF]